Shares of IMAC Holdings Inc (NASDAQ:IMAC) have earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price target of $7.00 for the company, according to Zacks. Zacks has also assigned IMAC an industry rank of 78 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine lowered shares of IMAC from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd.
IMAC (NASDAQ:IMAC) last announced its quarterly earnings results on Thursday, November 14th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.17). IMAC had a negative return on equity of 114.16% and a negative net margin of 41.07%. The company had revenue of $4.36 million for the quarter, compared to analyst estimates of $3.97 million.
IMAC Company Profile
IMAC Holdings, Inc operates a chain of integrated medicine and chiropractic regeneration centers. The company's outpatient clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions.
See Also: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMAC and related companies with MarketBeat.com's FREE daily email newsletter.